Core signal
What: Compared efficacy and tolerability of ADHD medications across 133 RCTs using a network meta-analysis.
PRO Summary
How to read this card
Evidence scope
Who: Analyzed children/adolescents and adults separately to evaluate drug-specific effects and side effects.
Use principle
Result: Methylphenidate was supported as the first-line choice for children and adolescents.
Evidence Reading
What to check when interpreting the evidence
Study typeType: NetworkMetaAnalysis
PopulationTarget: Children, adolescents, and adults with ADHD (133 RCTs)
EvidenceGrade: A
UseResult: Methylphenidate was supported as the first-line choice for children and adolescents.
Consultation Prep
Turn the card into questions before consultation
You can ask the specialist why this particular medication was chosen.
Record this as a question or context point before professional consultation.
Drug effects and side effects vary by individual, so maintain regular follow-ups.
Record this as a question or context point before professional consultation.
Limits
PRO use principles
Evidence scope
Limitations: Based on short-term trials (≤12 weeks). Long-term efficacy data are limited.
Hold individual application
Do not transfer group-level findings or review summaries directly to an individual case without considering family context, school context, comorbidity, and professional guidance.
Use principle
Disclaimer: This summary is for informational purposes only and does not prescribe, dose, or direct medication changes. Consult your physician for any medication decisions.
Professional consultation
Diagnosis, treatment, medication, educational planning, and ADHD management should be discussed with qualified professionals.
Scope Note
Notice and limits
Limitations: Based on short-term trials (≤12 weeks). Long-term efficacy data are limited.
Disclaimer: This summary is for informational purposes only and does not prescribe, dose, or direct medication changes. Consult your physician for any medication decisions.